A polymorphism in the type one complement receptor (CR1) involves an additional cysteine within the C3b/C4b binding domain that inhibits ligand binding. 2007

Daniel J Birmingham, and Fawzi Irshaid, and Katherine F Gavit, and Haikady N Nagaraja, and C Yung Yu, and Brad H Rovin, and Lee A Hebert
Division of Nephrology, Department of Internal Medicine, The Davis Heart and Lung Research Institute, The Ohio State University, Columbus, OH 43210, United States. Dan.Birmingham@osumc.edu <Dan.Birmingham@osumc.edu>

The type one complement receptor (CR1) contains a variable number of binding domains for C3b and C4b, formed through a nearly identical set of repeating units known as short consensus repeats (SCRs). Each SCR contains four cysteines that, by forming two disulfide bonds, impart a conformation critical for function. In this study, we identified a CR1 single nucleotide polymorphism (1597C>T) that results in an additional cysteine (483R>C) in SCR 8 of the N-terminal C3b/C4b binding domain, and occurring sporadically in corresponding SCRs of other repeated C3b/C4b binding domains. The normal carrier frequency for 483-C was 6.3% in 175 African Americans, and 2.4% in 153 Caucasians. In expression constructs containing one C3b/C4b binding domain, the 483-C residue reduced binding to C3b, C3bi, and C4b by over 80% (each p<0.0001), versus the wildtype construct. Full-length CR1 from 483-C carriers also exhibited reduced binding to C3b and C4b, although the effect was influenced by the total number of binding domains present. Race-matched comparisons between SLE patients (86 African Americans, 228 Caucasians) and the normal cohort showed that 483-C carrier status alone is not a risk factor for SLE or lupus nephritis. The physiological role of this polymorphism remains to be determined.

UI MeSH Term Description Entries
D008024 Ligands A molecule that binds to another molecule, used especially to refer to a small molecule that binds specifically to a larger molecule, e.g., an antigen binding to an antibody, a hormone or neurotransmitter binding to a receptor, or a substrate or allosteric effector binding to an enzyme. Ligands are also molecules that donate or accept a pair of electrons to form a coordinate covalent bond with the central metal atom of a coordination complex. (From Dorland, 27th ed) Ligand
D008180 Lupus Erythematosus, Systemic A chronic, relapsing, inflammatory, and often febrile multisystemic disorder of connective tissue, characterized principally by involvement of the skin, joints, kidneys, and serosal membranes. It is of unknown etiology, but is thought to represent a failure of the regulatory mechanisms of the autoimmune system. The disease is marked by a wide range of system dysfunctions, an elevated erythrocyte sedimentation rate, and the formation of LE cells in the blood or bone marrow. Libman-Sacks Disease,Lupus Erythematosus Disseminatus,Systemic Lupus Erythematosus,Disease, Libman-Sacks,Libman Sacks Disease
D008969 Molecular Sequence Data Descriptions of specific amino acid, carbohydrate, or nucleotide sequences which have appeared in the published literature and/or are deposited in and maintained by databanks such as GENBANK, European Molecular Biology Laboratory (EMBL), National Biomedical Research Foundation (NBRF), or other sequence repositories. Sequence Data, Molecular,Molecular Sequencing Data,Data, Molecular Sequence,Data, Molecular Sequencing,Sequencing Data, Molecular
D011485 Protein Binding The process in which substances, either endogenous or exogenous, bind to proteins, peptides, enzymes, protein precursors, or allied compounds. Specific protein-binding measures are often used as assays in diagnostic assessments. Plasma Protein Binding Capacity,Binding, Protein
D011951 Receptors, Complement Molecules on the surface of some B-lymphocytes and macrophages, that recognize and combine with the C3b, C3d, C1q, and C4b components of complement. Complement Receptors,Complement Receptor,Complement Receptor Type 1,Receptor, Complement
D003179 Complement C3b The larger fragment generated from the cleavage of COMPLEMENT C3 by C3 CONVERTASE. It is a constituent of the ALTERNATIVE PATHWAY C3 CONVERTASE (C3bBb), and COMPLEMENT C5 CONVERTASES in both the classical (C4b2a3b) and the alternative (C3bBb3b) pathway. C3b participates in IMMUNE ADHERENCE REACTION and enhances PHAGOCYTOSIS. It can be inactivated (iC3b) or cleaved by various proteases to yield fragments such as COMPLEMENT C3C; COMPLEMENT C3D; C3e; C3f; and C3g. C3b Complement,C3bi,Complement 3b,Complement Component 3b,Inactivated C3b,iC3b,C3b, Complement,C3b, Inactivated,Complement, C3b,Component 3b, Complement
D003545 Cysteine A thiol-containing non-essential amino acid that is oxidized to form CYSTINE. Cysteine Hydrochloride,Half-Cystine,L-Cysteine,Zinc Cysteinate,Half Cystine,L Cysteine
D003596 Cytosine A pyrimidine base that is a fundamental unit of nucleic acids.
D005787 Gene Frequency The proportion of one particular in the total of all ALLELES for one genetic locus in a breeding POPULATION. Allele Frequency,Genetic Equilibrium,Equilibrium, Genetic,Allele Frequencies,Frequencies, Allele,Frequencies, Gene,Frequency, Allele,Frequency, Gene,Gene Frequencies
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man

Related Publications

Daniel J Birmingham, and Fawzi Irshaid, and Katherine F Gavit, and Haikady N Nagaraja, and C Yung Yu, and Brad H Rovin, and Lee A Hebert
April 1987, Proceedings of the National Academy of Sciences of the United States of America,
Daniel J Birmingham, and Fawzi Irshaid, and Katherine F Gavit, and Haikady N Nagaraja, and C Yung Yu, and Brad H Rovin, and Lee A Hebert
February 1981, Journal of immunology (Baltimore, Md. : 1950),
Daniel J Birmingham, and Fawzi Irshaid, and Katherine F Gavit, and Haikady N Nagaraja, and C Yung Yu, and Brad H Rovin, and Lee A Hebert
February 1986, Journal of immunology (Baltimore, Md. : 1950),
Daniel J Birmingham, and Fawzi Irshaid, and Katherine F Gavit, and Haikady N Nagaraja, and C Yung Yu, and Brad H Rovin, and Lee A Hebert
May 1991, Proceedings of the National Academy of Sciences of the United States of America,
Daniel J Birmingham, and Fawzi Irshaid, and Katherine F Gavit, and Haikady N Nagaraja, and C Yung Yu, and Brad H Rovin, and Lee A Hebert
March 1985, Journal of immunology (Baltimore, Md. : 1950),
Daniel J Birmingham, and Fawzi Irshaid, and Katherine F Gavit, and Haikady N Nagaraja, and C Yung Yu, and Brad H Rovin, and Lee A Hebert
April 2004, Molecular immunology,
Daniel J Birmingham, and Fawzi Irshaid, and Katherine F Gavit, and Haikady N Nagaraja, and C Yung Yu, and Brad H Rovin, and Lee A Hebert
January 1998, The Biochemical journal,
Daniel J Birmingham, and Fawzi Irshaid, and Katherine F Gavit, and Haikady N Nagaraja, and C Yung Yu, and Brad H Rovin, and Lee A Hebert
April 2003, Immunology,
Daniel J Birmingham, and Fawzi Irshaid, and Katherine F Gavit, and Haikady N Nagaraja, and C Yung Yu, and Brad H Rovin, and Lee A Hebert
January 1990, Journal of immunology (Baltimore, Md. : 1950),
Daniel J Birmingham, and Fawzi Irshaid, and Katherine F Gavit, and Haikady N Nagaraja, and C Yung Yu, and Brad H Rovin, and Lee A Hebert
March 1994, The Journal of biological chemistry,
Copied contents to your clipboard!